WHO抗基孔肯雅病毒抗体国际标准品在小鼠模型中的保护滴度
研究评估了WHO抗基孔肯雅病毒抗体国际标准品1502/19在小鼠模型中的体内免疫保护作用。将1502/19稀释后给予naïve小鼠,24小时后用CHIKV分离株LR2006-OPY1攻击,未稀释组小鼠存活至研究终点(攻击后14天),表明该标准品可提供保护并建立保护滴度。结果确认单独体液免疫可提供保护,有助于未来疫苗评估中标准化保护阈值的阐明。
要点
- 未稀释的WHO国际标准品1502/19可保护小鼠抵抗致死性CHIKV攻击。
- 研究建立了可在体内达到的保护滴度,支持标准化保护阈值。
- 单独体液免疫足以提供针对CHIKV的保护。
核心结论
- WHO国际标准品1502/19在小鼠模型中可提供针对基孔肯雅病毒致死性攻击的保护。
研究设计与样本
- 研究将1502/19稀释后给予naïve小鼠,24小时后用CHIKV分离株LR2006-OPY1攻击,观察至攻击后14天。
主要发现
- 给予未稀释1502/19的小鼠在致死性感染后存活至研究终点(攻击后14天)。
关键数值与推荐
- 未稀释的1502/19可提供保护,确立可达到保护滴度。
临床怎么用
- 该结果有助于未来疫苗评估中标准化保护阈值的建立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chikungunya virus (CHIKV) is an arthritogenic mosquito-borne virus of public health concern, causing incapacitating febrile illness and, in some cases, chronic long-lasting recurring arthritis. The epidemic potential and unpredictable nature of CHIKV outbreaks provided a stimulus for establishing the WHO International Standard (1502/19) for anti-CHIKV antibodies in 2022. To enhance the value of this serological material, the in vivo immune protection of 1502/19 was assessed to determine the protective titre. Dilutions of 1502/19 were administered to naïve mice and circulating antibody levels measured prior to challenge 24 h later with CHIKV isolate LR2006-OPY1. Mice administered with undiluted 1502/19 survived an otherwise lethal infection to the end of the study (14 days post-challenge), indicating protection was afforded by 1502/19 and establishing a protective titre can be attained. Our results confirm that standalone humoral immunity can provide protection and aid in future vaccine evaluation by elucidating a standardised protective threshold.
引用
- Dowall SD, Findlay-Wilson S, Graham VA, et al. Protective titre of the WHO international standard for anti-chikungunya virus antibodies in a mouse model. Vaccine. 2026. PMID: 42430874. doi:10.1016/j.vaccine.2026.128927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。